Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics

Anil K. Malhotra, Debra A. Pinals, Caleb M. Adler, Igor Elman, Allan Clifton, David Pickar, Alan Breier

Research output: Contribution to journalArticle

485 Citations (Scopus)

Abstract

The N-methyl-d-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. We administered subanesthetic doses of the NMDA receptor antagonist ketamine in a double-blind, placebo-controlled design to 13 neuroleptic-free schizophrenic patients to investigate if schizophrenics will experience an exacerbation of psychotic symptoms and cognitive impairments with ketamine. We also examined whether schizophrenics experienced quantitative or qualitative differences in ketamine response in comparison to normal controls. Schizophrenics experienced a brief ketamine-induced exacerbation of positive and negative symptoms with further decrements in recall and recognition memory. They also displayed greater ketamine-induced impairments in free recall than normals. Qualitative differences included auditory hallucinations and paranoia in patients but not in normals. These data indicate that ketamine is associated with exacerbation of core psychotic and cognitive symptoms in schizophrenia. Moreover, ketamine may differentially affect cognition in schizophrenics in comparison to normal controls.

Original languageEnglish (US)
Pages (from-to)141-150
Number of pages10
JournalNeuropsychopharmacology
Volume17
Issue number3
DOIs
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Ketamine
Antipsychotic Agents
Schizophrenia
Paranoid Disorders
Neurobehavioral Manifestations
Hallucinations
Cognitive Dysfunction
Cognition
Placebos

Keywords

  • Cognition
  • Ketamine
  • NMDA
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. / Malhotra, Anil K.; Pinals, Debra A.; Adler, Caleb M.; Elman, Igor; Clifton, Allan; Pickar, David; Breier, Alan.

In: Neuropsychopharmacology, Vol. 17, No. 3, 09.1997, p. 141-150.

Research output: Contribution to journalArticle

Malhotra, Anil K. ; Pinals, Debra A. ; Adler, Caleb M. ; Elman, Igor ; Clifton, Allan ; Pickar, David ; Breier, Alan. / Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. In: Neuropsychopharmacology. 1997 ; Vol. 17, No. 3. pp. 141-150.
@article{33050a8f8cae48bcbdb399853c4a7246,
title = "Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics",
abstract = "The N-methyl-d-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. We administered subanesthetic doses of the NMDA receptor antagonist ketamine in a double-blind, placebo-controlled design to 13 neuroleptic-free schizophrenic patients to investigate if schizophrenics will experience an exacerbation of psychotic symptoms and cognitive impairments with ketamine. We also examined whether schizophrenics experienced quantitative or qualitative differences in ketamine response in comparison to normal controls. Schizophrenics experienced a brief ketamine-induced exacerbation of positive and negative symptoms with further decrements in recall and recognition memory. They also displayed greater ketamine-induced impairments in free recall than normals. Qualitative differences included auditory hallucinations and paranoia in patients but not in normals. These data indicate that ketamine is associated with exacerbation of core psychotic and cognitive symptoms in schizophrenia. Moreover, ketamine may differentially affect cognition in schizophrenics in comparison to normal controls.",
keywords = "Cognition, Ketamine, NMDA, Psychosis, Schizophrenia",
author = "Malhotra, {Anil K.} and Pinals, {Debra A.} and Adler, {Caleb M.} and Igor Elman and Allan Clifton and David Pickar and Alan Breier",
year = "1997",
month = "9",
doi = "10.1016/S0893-133X(97)00036-5",
language = "English (US)",
volume = "17",
pages = "141--150",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics

AU - Malhotra, Anil K.

AU - Pinals, Debra A.

AU - Adler, Caleb M.

AU - Elman, Igor

AU - Clifton, Allan

AU - Pickar, David

AU - Breier, Alan

PY - 1997/9

Y1 - 1997/9

N2 - The N-methyl-d-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. We administered subanesthetic doses of the NMDA receptor antagonist ketamine in a double-blind, placebo-controlled design to 13 neuroleptic-free schizophrenic patients to investigate if schizophrenics will experience an exacerbation of psychotic symptoms and cognitive impairments with ketamine. We also examined whether schizophrenics experienced quantitative or qualitative differences in ketamine response in comparison to normal controls. Schizophrenics experienced a brief ketamine-induced exacerbation of positive and negative symptoms with further decrements in recall and recognition memory. They also displayed greater ketamine-induced impairments in free recall than normals. Qualitative differences included auditory hallucinations and paranoia in patients but not in normals. These data indicate that ketamine is associated with exacerbation of core psychotic and cognitive symptoms in schizophrenia. Moreover, ketamine may differentially affect cognition in schizophrenics in comparison to normal controls.

AB - The N-methyl-d-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. We administered subanesthetic doses of the NMDA receptor antagonist ketamine in a double-blind, placebo-controlled design to 13 neuroleptic-free schizophrenic patients to investigate if schizophrenics will experience an exacerbation of psychotic symptoms and cognitive impairments with ketamine. We also examined whether schizophrenics experienced quantitative or qualitative differences in ketamine response in comparison to normal controls. Schizophrenics experienced a brief ketamine-induced exacerbation of positive and negative symptoms with further decrements in recall and recognition memory. They also displayed greater ketamine-induced impairments in free recall than normals. Qualitative differences included auditory hallucinations and paranoia in patients but not in normals. These data indicate that ketamine is associated with exacerbation of core psychotic and cognitive symptoms in schizophrenia. Moreover, ketamine may differentially affect cognition in schizophrenics in comparison to normal controls.

KW - Cognition

KW - Ketamine

KW - NMDA

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030749913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030749913&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(97)00036-5

DO - 10.1016/S0893-133X(97)00036-5

M3 - Article

VL - 17

SP - 141

EP - 150

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -